<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="mbt214332" xml:lang="en" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jats-oasis2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Microb Biotechnol</journal-id><journal-id journal-id-type="iso-abbrev">Microb Biotechnol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1751-7915</journal-id><journal-id journal-id-type="publisher-id">MBT2</journal-id><journal-title-group><journal-title>Microbial Biotechnology</journal-title></journal-title-group><issn pub-type="epub">1751-7915</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">10527214</article-id><article-id pub-id-type="pmid">37606280</article-id><article-id pub-id-type="doi">10.1111/1751-7915.14332</article-id><article-id pub-id-type="publisher-id">MBT214332</article-id><article-id pub-id-type="other">MICROBIO-2023-232-RA.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Design of a chimeric glycosyltransferase OleD for the site&#x02010;specific O&#x02010;monoglycosylation of 3&#x02010;hydroxypyridine in nosiheptide</article-title><alt-title alt-title-type="right-running-head">biosynthesis of monoglycosyl nosiheptide</alt-title><alt-title alt-title-type="left-running-head">Zhao et al.</alt-title></title-group><contrib-group><contrib id="mbt214332-cr-0001" contrib-type="author"><name><surname>Zhao</surname><given-names>Ling</given-names></name><xref rid="mbt214332-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mbt214332-cr-0002" contrib-type="author"><name><surname>Xu</surname><given-names>Yuncong</given-names></name><xref rid="mbt214332-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mbt214332-cr-0003" contrib-type="author"><name><surname>Chen</surname><given-names>Manting</given-names></name><xref rid="mbt214332-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mbt214332-cr-0004" contrib-type="author"><name><surname>Wu</surname><given-names>Lingrui</given-names></name><xref rid="mbt214332-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mbt214332-cr-0005" contrib-type="author"><name><surname>Li</surname><given-names>Meng</given-names></name><xref rid="mbt214332-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mbt214332-cr-0006" contrib-type="author"><name><surname>Lu</surname><given-names>Yuanyuan</given-names></name><xref rid="mbt214332-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="mbt214332-cr-0007" contrib-type="author" corresp="yes"><name><surname>Lu</surname><given-names>Meiling</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8738-987X</contrib-id><xref rid="mbt214332-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>lumeiling@cpu.edu.cn</email></address></contrib><contrib id="mbt214332-cr-0008" contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Yijun</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4920-152X</contrib-id><xref rid="mbt214332-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>yjchen@cpu.edu.cn</email></address></contrib><contrib id="mbt214332-cr-0009" contrib-type="author" corresp="yes"><name><surname>Wu</surname><given-names>Xuri</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0933-5902</contrib-id><xref rid="mbt214332-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>xuriwu@cpu.edu.cn</email></address></contrib></contrib-group><aff id="mbt214332-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Chemical Biology</named-content>
<institution>College of Life Sciences and Technology, China Pharmaceutical University</institution>
<city>Nanjing</city>
<named-content content-type="country-part">Jiangsu Province</named-content>
<country country="CN">PR China</country>
</aff><aff id="mbt214332-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Biochemistry</named-content>
<institution>College of Life Sciences and Technology, China Pharmaceutical University</institution>
<city>Nanjing</city>
<named-content content-type="country-part">Jiangsu Province</named-content>
<country country="CN">PR China</country>
</aff><aff id="mbt214332-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Marine Pharmacy</named-content>
<institution>College of Life Sciences and Technology, China Pharmaceutical University</institution>
<city>Nanjing</city>
<named-content content-type="country-part">Jiangsu Province</named-content>
<country country="CN">PR China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Meiling Lu and Xuri Wu, Department of Biochemistry, College of Life Sciences and Technology, China Pharmaceutical University, 639 Longmian Road, Nanjing, Jiangsu Province 211198, PR China.<break/>
Email: <email>lumeiling@cpu.edu.cn</email> and <email>xuriwu@cpu.edu.cn</email>
<break/>
Yijun Chen, Laboratory of Chemical Biology, College of Life Sciences and Technology, China Pharmaceutical University, 639 Longmian Road, Nanjing, Jiangsu Province 211198, PR China.<break/>
Email: <email>yjchen@cpu.edu.cn</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2023</year></pub-date><volume>16</volume><issue seq="100">10</issue><issue-id pub-id-type="doi">10.1111/mbt2.v16.10</issue-id><fpage>1971</fpage><lpage>1984</lpage><history>
<date date-type="rev-recd"><day>03</day><month>8</month><year>2023</year></date>
<date date-type="received"><day>01</day><month>6</month><year>2023</year></date>
<date date-type="accepted"><day>07</day><month>8</month><year>2023</year></date>
</history><permissions><!--&#x000a9; 2023 John Wiley & Sons Ltd and Society for Applied Microbiology--><copyright-statement content-type="article-copyright">&#x000a9; 2023 The Authors. <italic toggle="yes">Microbial Biotechnology</italic> published by Applied Microbiology International and John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:MBT2-16-1971.pdf"/><abstract><title>Abstract</title><p>To identify the potential role of the 3&#x02010;hydroxyl group of the pyridine ring in nosiheptide (NOS) for its antibacterial activity against Gram&#x02010;positive pathogens, enzymatic glycosylation was utilized to regio&#x02010;selectively create a monoglycosyl NOS derivative, NOS&#x02010;G. For this purpose, we selected OleD, a UDP glycosyltransferase from <italic toggle="no">Streptomyces antibioticus</italic> that has a low productivity for NOS&#x02010;G. Activity of the enzyme was increased by swapping domains derived from OleI, both single and in combination. Activity enhancement was best in mutant OleD&#x02010;10 that contained four OleI domains. This chimer was engineered by site&#x02010;directed mutagenesis (single and in combination) to increase its activity further, whereby variants were screened using a newly&#x02010;established colorimetric assay. OleD&#x02010;10 with I117F and T118G substitutions (FG) had an increased NOS&#x02010;G productivity of 56%, approximately 70 times higher than that of wild&#x02010;type OleD. The reason for improved activity of FG towards NOS was structurally attributed to a closer distance (&#x0003c;3&#x02009;&#x000c5;) between NOS/sugar donor and the catalytic amino acid H25. The engineered enzyme allowed sufficient activity to demonstrate that the produced NOS&#x02010;G had enhanced stability and aqueous solubility compared to NOS. Using a murine MRSA infection model, it was established that NOS&#x02010;G resulted in partial protection within 20&#x02009;h of administration and delayed the death of infected mice. We conclude that 3&#x02010;hydroxypyridine is a promising site for structural modification of NOS, which may pave the way for producing nosiheptide derivatives as a potential antibiotic for application in clinical treatment.</p></abstract><abstract abstract-type="graphical"><p>A monoglycosyl nosiheptide, which exhibit improved solubility and stability compared to nosiheptide, was created by enzymatic glycosylation. By enzyme engineering coupled with a new colorimetric method, a chimeric enzyme with approximately 70 times higher activity was constructed. These findings suggest the potential for structural modifications at the 3&#x02010;hydroxypyridine site of nosiheptide to develop novel nosiheptide derivatives with improved properties for clinical treatment.<boxed-text position="anchor" content-type="graphic" id="mbt214332-blkfxd-0001"><graphic xlink:href="MBT2-16-1971-g001.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Key Research and Development Program of China
</institution><institution-id institution-id-type="doi">10.13039/501100012166</institution-id></institution-wrap></funding-source><award-id>2018YFA0902000</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>81973214</award-id></award-group><award-group id="funding-0003"><funding-source>Key Research and Development Project of Guangdong Province</funding-source><award-id>2022B1111070004</award-id></award-group><award-group id="funding-0004"><funding-source>&#x0201c;Double First&#x02010;Class&#x0201d; University project</funding-source><award-id>CPU2022QZ08</award-id></award-group><award-group id="funding-0005"><funding-source>National Innovation and Entrepreneurship Training Program for Undergraduate</funding-source><award-id>202310316020Z</award-id></award-group></funding-group><counts><fig-count count="8"/><table-count count="2"/><page-count count="14"/><word-count count="8519"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.4 mode:remove_FC converted:27.09.2023</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="MBT214332-cit-2001">
<string-name>
<surname>Zhao</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>Y.</given-names>
</string-name> et al. (<year>2023</year>) <article-title>Design of a chimeric glycosyltransferase OleD for the site&#x02010;specific O&#x02010;monoglycosylation of 3&#x02010;hydroxypyridine in nosiheptide</article-title>. <source>Microbial Biotechnology</source>, <volume>16</volume>, <fpage>1971</fpage>&#x02013;<lpage>1984</lpage>. Available from: <pub-id pub-id-type="doi">10.1111/1751-7915.14332</pub-id>
<pub-id pub-id-type="pmid">37606280</pub-id></mixed-citation>
</p><fn-group id="mbt214332-ntgp-0001"><fn fn-type="equal" id="mbt214332-note-0101"><p>Ling Zhao, Yuncong Xu and Manting Chen contributed equally to this work.</p></fn></fn-group></notes></front><body id="mbt214332-body-0001"><sec id="mbt214332-sec-0001"><title>INTRODUCTION</title><p>Nosiheptide (NOS), originally discovered as a product of <italic toggle="yes">Streptomyces actuosus</italic> (Benazet et al.,&#x000a0;<xref rid="mbt214332-bib-0002" ref-type="bibr">1980</xref>), is a typical representative of an e&#x02010;series thiopeptide. This compound exhibits a nanomolar antibacterial potency <italic toggle="yes">in vitro</italic> against various Gram&#x02010;positive pathogens, including methicillin&#x02010;resistant <italic toggle="yes">staphylococcus aureus</italic> (MRSA), methicillin&#x02010;resistant <italic toggle="yes">Staphylococcus epidermidis</italic> (MRSE), vancomycin&#x02010;resistant <italic toggle="yes">Enterococci</italic> (VRE) and <italic toggle="yes">Clostridium difficile</italic> (Bagley et al.,&#x000a0;<xref rid="mbt214332-bib-0001" ref-type="bibr">2015</xref>; Haste et al.,&#x000a0;<xref rid="mbt214332-bib-0009" ref-type="bibr">2012</xref>; Tsutsumi et al.,&#x000a0;<xref rid="mbt214332-bib-0025" ref-type="bibr">2014</xref>). As previously reported, NOS exerts its antibacterial effect by inserting itself into the GTPase&#x02010;associated centre (GAC) of the bacterial ribosome, which is formed by protein L11 and 23S rRNA of the 50S subunit, consequently disturbing bacterial protein biosynthesis (Harms et al.,&#x000a0;<xref rid="mbt214332-bib-0008" ref-type="bibr">2008</xref>). This highly specific mode of action and its prominent minimal inhibitory concentration (MIC) suggested NOS could be a promising &#x0201c;last&#x02010;resort&#x0201d; antibiotic against Gram&#x02010;positive pathogens, in particular to combat multi&#x02010;drug resistant, extensively resistant and pan&#x02010;drug resistant strains (Magiorakos et al.,&#x000a0;<xref rid="mbt214332-bib-0020" ref-type="bibr">2012</xref>), potentially providing an alternative to vancomycin and its derivatives. However, a lack of <italic toggle="yes">in vivo</italic> effects provides a barrier against clinical applications of NOS. Thus far, NOS is only approved as a feed additive for livestock (Xie et al.,&#x000a0;<xref rid="mbt214332-bib-0030" ref-type="bibr">2019</xref>).</p><p>It is assumed that the failure of NOS to act <italic toggle="yes">in vivo</italic> is due to its poor aqueous solubility and its structural instability in blood (Fan et al.,&#x000a0;<xref rid="mbt214332-bib-0005" ref-type="bibr">2021</xref>; Vinogradov &#x00026; Suga,&#x000a0;<xref rid="mbt214332-bib-0026" ref-type="bibr">2020</xref>). To address this issue, structural modifications of NOS have been produced by chemical and biosynthetic methods (Fan et al.,&#x000a0;<xref rid="mbt214332-bib-0005" ref-type="bibr">2021</xref>; Liu et al.,&#x000a0;<xref rid="mbt214332-bib-0019" ref-type="bibr">2013</xref>; Tan et al.,&#x000a0;<xref rid="mbt214332-bib-0024" ref-type="bibr">2022</xref>; Vinogradov &#x00026; Suga,&#x000a0;<xref rid="mbt214332-bib-0026" ref-type="bibr">2020</xref>; Zhang, Guo, et al.,&#x000a0;<xref rid="mbt214332-bib-0032" ref-type="bibr">2020</xref>), but derivatives with a confirmed <italic toggle="yes">in vivo</italic> activity have not been achieved so far. NOS contains a dehydroalanine tail and an indolic acid moiety, and owing to its structural complexity, there are few regions suitable to be modified (Figure&#x000a0;<xref rid="mbt214332-fig-0001" ref-type="fig">1</xref>). This largely limits the diversity of NOS&#x02010;based analogues for drug development. To increase the variation in potential structural variants, the central 3&#x02010;hydroxypyridine ring of NOS would be an ideal target for modification, based on its chemical reactivity, but the required deep&#x02010;cleft binding mode in the GAC of the bacterial ribosome, which is crucial for its mode of action (Tsutsumi et al.,&#x000a0;<xref rid="mbt214332-bib-0025" ref-type="bibr">2014</xref>), might prevent modifications of the 3&#x02010;hydroxypyridine group, as it might inactivate the compound. As a consequence, 3&#x02010;hydroxypyridine&#x02010;modified derivatives are uncommonly created or explored for antibacterial effectiveness (Fan et al.,&#x000a0;<xref rid="mbt214332-bib-0005" ref-type="bibr">2021</xref>; Kimber &#x00026; Moody,&#x000a0;<xref rid="mbt214332-bib-0015" ref-type="bibr">2008</xref>; Liu et al.,&#x000a0;<xref rid="mbt214332-bib-0019" ref-type="bibr">2013</xref>; Tan et al.,&#x000a0;<xref rid="mbt214332-bib-0024" ref-type="bibr">2022</xref>; Vinogradov &#x00026; Suga,&#x000a0;<xref rid="mbt214332-bib-0026" ref-type="bibr">2020</xref>; Wojtas et al.,&#x000a0;<xref rid="mbt214332-bib-0029" ref-type="bibr">2016</xref>; Zhang, Guo, et al.,&#x000a0;<xref rid="mbt214332-bib-0032" ref-type="bibr">2020</xref>).</p><fig position="float" fig-type="FIGURE" id="mbt214332-fig-0001"><label>FIGURE 1</label><caption><p>Conceived monoglycosylation of the 3&#x02010;hydroxypyridine group of nosiheptide. The dehydroalanine tail and indolic acid moiety of NOS are marked in purple, and 3&#x02010;hydroxypyridine is shown in red. A glucose moiety attached to NOS to give monoglycosylated NOS is given in blue.</p></caption><graphic xlink:href="MBT2-16-1971-g004" position="anchor" id="jats-graphic-3"/></fig><p>Glycosylation can potentially lead to altered functions of drugs, and this approach is used to inactivate an antibiotic in its producing strain to generate self&#x02010;resistance, as exemplified by naturally produced glycosylated macrolides and ansamycins (Liang et al.,&#x000a0;<xref rid="mbt214332-bib-0018" ref-type="bibr">2015</xref>). Here, we assessed if specific monoglycosylation of the 3&#x02010;hydroxypyridine group of NOS would be feasible to change its activity. Given the similar reactivity of three hydroxyl groups present in NOS (Figure&#x000a0;<xref rid="mbt214332-fig-0001" ref-type="fig">1</xref>), site&#x02010;specific O&#x02010;monoglycosylation of the 3&#x02010;hydroxypyridine core by a glycosyltransferase was our method of choice, as chemical modification would be uncontrollable for site&#x02010;selectivity (Zhao et al.,&#x000a0;<xref rid="mbt214332-bib-0036" ref-type="bibr">2020</xref>). Although there are at least 116 families of glycosyltransferases deposited in the CAZy database (<ext-link xlink:href="http://www.cazy.org/" ext-link-type="uri">http://www.cazy.org/</ext-link>), the relatively bulky and rigid structure of NOS complicated the search for a suitable enzyme, which had to combine site&#x02010;selectivity with a broad substrate specificity.</p><p>To this purpose, we initially screened 23 enzymes and identified UDP&#x02010;glycosyltransferase OleD from <italic toggle="yes">Streptomyces antibioticus</italic> as a suitable candidate. This well&#x02010;explored member of GT&#x02010;B fold enzymes can glycosylate diverse natural or artificial substrates (Bolam et al.,&#x000a0;<xref rid="mbt214332-bib-0003" ref-type="bibr">2007</xref>; Gantt et al.,&#x000a0;<xref rid="mbt214332-bib-0007" ref-type="bibr">2013</xref>; Hughes et al.,&#x000a0;<xref rid="mbt214332-bib-0011" ref-type="bibr">2020</xref>; Zhou et al.,&#x000a0;<xref rid="mbt214332-bib-0037" ref-type="bibr">2013</xref>). We found that the enzyme OleD was indeed capable of O&#x02010;glycosylating 3&#x02010;hydroxypyridine in NOS using UDP&#x02010;glucose (UDPG) as the sugar donor, albeit with a very low efficiency. To improve its efficiency, we engineered OleD by swapping functional enzyme domains with domains from another glycosyltransferase. The approach successfully created a chimera that combined OleD and OleI domains with excellent activity towards the 3&#x02010;hydroxypyridine group of NOS. Following targeted site&#x02010;directed mutagenesis to increase enzyme activity even further, enough monoglycosyl NOS (NOS&#x02010;G) was produced to test its activity <italic toggle="yes">in vivo</italic>. NOS&#x02010;G displayed a better protection effect in MRSA&#x02010;infected mice compared to unmodified NOS, indicating that 3&#x02010;hydroxypyridine is a permissible target site for structural modification of NOS. Thus, this study not only provides a new method to create chimeric enzymes for site&#x02010;specific glycosylation of NOS but also for the first time demonstrates a possible target site to improve the druggability of NOS.</p></sec><sec id="mbt214332-sec-0002"><title>EXPERIMENTAL METHODS</title><sec id="mbt214332-sec-0003"><title>Chemicals and reagents</title><p>The bacterial strains, plasmids, restriction endonucleases and Quick Mutation kit were obtained from Vazyme Biotech Co., Ltd. Materials for protein crystallization were purchased from Hampton Research Company. The gene encoding OleD (GenBank no. WP_063854495.1) and chimeras were synthesized by Suzhou Genewiz Biotechnology Co., Ltd. HPLC&#x02010;grade reagents were obtained from Aladdin Bio&#x02010;Chem Technology Co., Ltd. NOS was prepared according to the procedures previously described Jiang et al.&#x000a0;(<xref rid="mbt214332-bib-0012" ref-type="bibr">2015</xref>).</p></sec><sec id="mbt214332-sec-0004"><title>HPLC and LC&#x02010;MS analytical methods</title><p>HPLC analysis was performed using Shimadzu Nexera LC&#x02010;40 on a YMC&#x02010;Pack ODS column (5&#x02009;&#x003bc;m, 150&#x02009;&#x000d7;&#x02009;4.6&#x02009;mm) with mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile) at 30&#x000b0;C and 330&#x02009;nm with a flow rate of 1&#x02009;mL/min. The gradient elution was conducted as follows: 10%&#x02013;50% mobile phase B in 6&#x02009;min, 50%&#x02013;70% mobile phase B in 16&#x02009;min and 70%&#x02013;90% mobile phase B in 4&#x02009;min. The production rate of NOS&#x02010;G (%) was calculated as <italic toggle="yes">A</italic>
<sub>
<italic toggle="yes">e</italic>
</sub>/<italic toggle="yes">A</italic>
<sub>0</sub>, where <italic toggle="yes">A</italic>
<sub>
<italic toggle="yes">e</italic>
</sub> is the peak area of a produced NOS&#x02010;G and <italic toggle="yes">A</italic>
<sub>0</sub> is the total area of NOS and NOS&#x02010;G combined. Liquid chromatography (LC)&#x02010;mass spectrometry (MS) analysis was conducted with a Shimadzu LCMS&#x02010;8045 spectrometer with parameters as summarized in Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="mbt214332-sec-0005"><title>Expression of enzymes in <italic toggle="no">E. coli</italic>
</title><p>The genes encoding 23 selected glycosyltransferases and glycosynthases were synthesized and individually inserted into corresponding pET vectors, including pET22b(+), pET28a(+), pET33b(+) and pET302, for heterogenous expression in <italic toggle="yes">E. coli</italic> BL21(DE3) (Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S2</xref>). Transformants were selected and proteins were expressed using described procedures (Zhao et al.,&#x000a0;<xref rid="mbt214332-bib-0036" ref-type="bibr">2020</xref>) with expression conditions displayed in Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S3</xref>. Subsequently, the expression levels of the 23 enzymes were compared by sodium dodecyl sulfate&#x02010;polyacrylamide gel electrophoresis (SDS&#x02010;PAGE) analysis.</p></sec><sec id="mbt214332-sec-0006"><title>Screening of enzymes for the biosynthesis of glycosylated NOS</title><p>
<italic toggle="yes">Escherichia coli</italic> cells (0.5&#x02009;g) expressing OleD (or chimers or variants thereof) were resuspended in 5&#x02009;mL of 50&#x02009;mM Tris&#x02010;HCl buffer (pH&#x02009;8.0) and ultrasonically disrupted for 5&#x02009;min in an ice bath. The cell extract was centrifugated at 12,000&#x02009;<bold>
<italic toggle="yes">g</italic>
</bold> for 15&#x02009;min, and the supernatant was used for determination of enzyme activity. For this, a 2&#x02009;mL reaction mixture consisting of 1&#x02009;mg/mL NOS, 3&#x02009;mg/mL UDPG, 1&#x02009;mL crude protein extract, 0.2 mL DMSO and 50&#x02009;mM Tris&#x02010;HCl (pH&#x02009;8.0) was incubated with conditions listed in Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S4</xref>, and then quenched by adding 4&#x02009;mL of methanol. After centrifugation, the resulting supernatant was analysed by HPLC and LC&#x02010;MS. The same procedure was followed to determine the glycosylation of NOS by other enzymes, using the reaction conditions shown in Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S4</xref>.</p><p>For structural characterization of monoglycosylated NOS, the OleD&#x02010;catalysed reaction was scaled to 10 batches of 0.5&#x02009;L each. All 10 batches were individually conducted and combined for ethyl acetate extraction. The resulting extract was subjected to semi&#x02010;preparative HPLC for the purification of glycosylated NOS on a YMC preparative ODS column (5&#x02009;&#x003bc;m, 250&#x02009;&#x000d7;&#x02009;10&#x02009;mm) with an isocratic elution of 35% acetonitrile in water (0.1% formic acid) at a flow rate of 4&#x02009;mL/min for 20&#x02009;min. The purified NOS derivative, dissolved in DMSO&#x02010;<italic toggle="yes">d</italic>
<sub>6</sub>, had a purity over 98% and was structurally identified on a Bruker Advance AMX600 NMR spectrometer.</p></sec><sec id="mbt214332-sec-0007"><title>Construction and purification of chimeric OleD&#x02010;1 to OleD&#x02010;10</title><p>The amino acid sequences of OleD (GenBank no. WP_063854495.1) and OleI (GenBank no. WP_030778152.1) were aligned to locate regions of divergence for chimera construction. The genes of all designed OleD&#x02010;chimeras were synthesized with a His&#x02010;tag installed at the C&#x02010;terminal inserted into pET22b(+) for IPTG&#x02010;induced expression in <italic toggle="yes">E. coli</italic> BL21 according to the expression conditions for OleD. After expression, wild&#x02010;type OleD and chimeras were purified using a His&#x02010;TALON metal nickel affinity resin (Takara Bio) in a gradient with Tris&#x02010;HCl buffer (50&#x02009;mM Tris&#x02010;HCl, 200&#x02009;mM NaCl, pH&#x02009;9.0) containing 10&#x02013;500&#x02009;mM of imidazole.</p></sec><sec id="mbt214332-sec-0008"><title>Knockout of <italic toggle="no">malZ</italic> by &#x003bb; red gene recombination</title><p>The &#x003bb; Red gene recombination technology (Zhang, Xu, et al.,&#x000a0;<xref rid="mbt214332-bib-0035" ref-type="bibr">2020</xref>) was employed to knock out the <italic toggle="yes">malZ</italic> gene (GenBank: CAD6014888.1) in <italic toggle="yes">E. coli</italic> BL21(DE3). Primers <italic toggle="yes">malZ</italic>&#x02010;homo&#x02010;F and <italic toggle="yes">malZ</italic>&#x02010;homo&#x02010;R (Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S5</xref>) containing 50&#x02009;bp flanking sequences from <italic toggle="yes">malZ</italic> were used to amplify the homologous substitution fragment of <italic toggle="yes">malZ</italic> (&#x00394;<italic toggle="yes">malZ</italic>), using plasmid pKD3 as a template. The &#x00394;<italic toggle="yes">malZ</italic> fragment was transformed into <italic toggle="yes">E. coli</italic> BL21(DE3) containing pKD46 for recombination to produce <italic toggle="yes">E. coli</italic> &#x00394;<italic toggle="yes">malZ</italic>&#x02010;pKD46. The temperature&#x02010;sensitive pCP20 was electro&#x02010;transformed into <italic toggle="yes">E. coli</italic> &#x00394;<italic toggle="yes">malZ</italic>&#x02010;pKD46 to eliminate chloramphenicol resistance. Finally, all tool plasmids were removed at 42&#x000b0;C to obtain <italic toggle="yes">E. coli malZ</italic>
<sup>&#x02212;</sup>
<italic toggle="yes">KO</italic> lacking a functional <italic toggle="yes">malZ</italic>, which was verified by primers <italic toggle="yes">malZ</italic>&#x02010;verify&#x02010;F and <italic toggle="yes">malZ</italic>&#x02010;verify&#x02010;R as shown in Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S5</xref>.</p></sec><sec id="mbt214332-sec-0009"><title>Colorimetric method for glycosyltransferase screening</title><p>For the recyclable production of fructose, the gene of OleD&#x02010;10 was inserted into a pETDuet&#x02010;<italic toggle="yes">AtSUS</italic> containing a sucrose synthase gene from <italic toggle="yes">Arabidopsis thaliana</italic> (GenBank: OAP16120.1) using <italic toggle="yes">Nco</italic>I and <italic toggle="yes">Hin</italic>dIII. The resulting co&#x02010;expression plasmid pETDuet&#x02010;<italic toggle="yes">OA</italic> was chemically transformed into <italic toggle="yes">E. coli malZ</italic>
<sup>&#x02212;</sup>
<italic toggle="yes">KO</italic> to give <italic toggle="yes">E. coli malZ</italic>
<sup>&#x02212;</sup>
<italic toggle="yes">KO&#x02010;OA&#x02010;10</italic>. Both coupling enzymes were co&#x02010;expressed in a 96&#x02010;well plate with a culture of 500&#x02009;&#x003bc;L under optimized conditions including 0.2&#x02009;mM IPTG and 12&#x02009;h of incubation at 25&#x000b0;C. After centrifugation, the <italic toggle="yes">E. coli</italic> cells were lysed with 1.2&#x02009;mg/mL lysozyme (Sangon Biotech) at 20&#x000b0;C for 30&#x02009;min in 50&#x02009;mM Tris&#x02013;HCl, pH&#x02009;8.0, 5&#x02009;mM MgCl<sub>2</sub>. As previously described (Zhang, Xu, et al.,&#x000a0;<xref rid="mbt214332-bib-0035" ref-type="bibr">2020</xref>; Zhao et al.,&#x000a0;<xref rid="mbt214332-bib-0036" ref-type="bibr">2020</xref>), the 100&#x02009;&#x003bc;L reaction mixture consisted of 0.8&#x02009;mg/mL NOS, 2.5&#x02009;mg/mL UDPG, 175&#x02009;mg/mL sucrose and 60&#x02009;&#x003bc;L crude extract containing OleD&#x02010;10 and <italic toggle="yes">At</italic>SUS. The reaction was conducted at 30 &#x000b0;C for 6&#x02009;h, terminated by boiling for 5&#x02009;min and centrifugated. Then, 60&#x02009;&#x003bc;L was mixed with an equal volume of DNS solution for colorization and the absorbance was measured at 540&#x02009;nm. A standard curve with variable fructose concentrations was produced using the values of A<sub>540</sub> (<italic toggle="yes">Y</italic>) and the fructose concentration (<italic toggle="yes">X</italic>). A regression equation for fructose at concentrations below 0.1&#x02009;mM was derived as <italic toggle="yes">Y</italic>&#x02009;=&#x02009;2.037<italic toggle="yes">X</italic>&#x02212;0.031 (<italic toggle="yes">R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.999), while above 0.1&#x02009;mM it was <italic toggle="yes">Y</italic>&#x02009;=&#x02009;1.703<italic toggle="yes">X</italic>&#x02212;0.009 (<italic toggle="yes">R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.995). Within this linearity, the recovery rate, limit of detection (LoD) and limit of quantitation (LoQ) of the colorimetric method were determined with reference to the literature (Fernando &#x00026; Soysa,&#x000a0;<xref rid="mbt214332-bib-0006" ref-type="bibr">2015</xref>).</p></sec><sec id="mbt214332-sec-0010"><title>Co&#x02010;crystallization of chimeric OleD&#x02010;10 and UDPG</title><p>Co&#x02010;crystallization of OleD&#x02010;10 and UDPG was conducted at 16 &#x000b0;C using the sitting&#x02010;drop vapour&#x02010;diffusion method. After a systematical screening, the crystallization conditions were set as 10% PEG200 (v/v), 21% PEG8000 (w/v), 0.1&#x02009;M Bis&#x02010;Tris propane (pH&#x02009;9.5), 0.18&#x02009;mM purified OleD&#x02010;10 and 2&#x02009;mM UDPG, which resulted in a good crystal morphology. Diffraction analysis of the OleD&#x02010;10&#x02010;UDPG crystal was conducted at the Shanghai Synchrotron Light Source BL17U Biomolecule Line Station. The data were processed by HKL3000 or XDS, and the structure of OleD (PDB: 2IYF) was used as a model for substitution. The structural refinement was performed using Penix and WinCoot to obtain the protein crystal structure.</p></sec><sec id="mbt214332-sec-0011"><title>Engineering and screening of OleD&#x02010;10 variants</title><p>For site&#x02010;directed mutagenesis, a commercial kit from Beyotime Biotechnology Co., Ltd. was used. Alanine scanning and saturation mutagenesis of OleD&#x02010;10 were conducted with pETDuet&#x02010;<italic toggle="yes">OA</italic> as the template. All primers were optimized for codon preference in <italic toggle="yes">E. coli</italic> as shown in Tables&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S6 and S7</xref>. All mutants were preliminarily screened by the colorimetric method as described above. The activity of OleD&#x02010;10 variants showing significant improvement in catalytic efficiency was verified by HPLC.</p></sec><sec id="mbt214332-sec-0012"><title>Molecular docking and dynamics simulations</title><p>The structure of FG was constructed by RoseTTAFold (<ext-link xlink:href="http://new.robetta.org/" ext-link-type="uri">http://new.robetta.org/</ext-link>), a deep learning&#x02010;based modelling method (Khersonsky et al.,&#x000a0;<xref rid="mbt214332-bib-0014" ref-type="bibr">2018</xref>), using the crystal structure of OleD&#x02010;10 as a template. According to our previous work (Xu et al.,&#x000a0;<xref rid="mbt214332-bib-0031" ref-type="bibr">2022</xref>), along with the energy minimization of NOS and UDPG, the structure of OleD&#x02010;10 and modelled FG were employed to conduct flexible docking between enzyme and ligands with default parameter settings in the MOE, respectively. The GROMACS 4.5.4 program package in the Ubuntu 14.04 operating system was used for MD simulations. The systems were equilibrated using two consecutive 100&#x02009;ps position&#x02010;restrained dynamics runs in the NVT and NPT ensembles, respectively. Subsequently, the equilibrated systems were subjected to 200&#x02009;ns production MD runs with a time step of 10&#x02009;ps. The Gmmpbsa tool was used to calculate the binding free energy of the catalytic complex using the molecular mechanics generalized Born surface area (MM/GBSA) method implemented in AMBER16.50.</p></sec><sec id="mbt214332-sec-0013"><title>Kinetic analysis of OleD and its variants</title><p>To determine the kinetic properties towards NOS, 1.0&#x02009;mL reaction mixture containing 5&#x02009;mM UDPG, a varying concentration of NOS (from 0.01 to 2&#x02009;mM), 0.2&#x02009;mg of purified OleD or its variants, 0.1 mL DMSO 5&#x02009;mM MgCl<sub>2</sub>&#x000a0;and 50&#x02009;mM Tris&#x02010;HCl pH&#x02009;9.0 was incubated at 35&#x000b0;C for 4&#x02009;h. The kinetics for UDPG were determined with concentrations ranging from 0.41 to 19.7&#x02009;mM UDPG. Kinetic analysis was performed with Origin 8.0. One unit of enzyme activity was defined to produce 1&#x02009;mmol of NOS&#x02010;G per minute per mg of protein.</p></sec><sec id="mbt214332-sec-0014"><title>Solubility and stability test of NOS&#x02010;G</title><p>To check the solubility of the compounds, 0.5&#x02009;mg/mL NOS&#x02010;G or NOS was prepared in 1&#x02009;mL aqueous solution containing 5% DMSO and buffer with pH values ranging from 2.0 to 7.0 (0.1&#x02009;M glycine&#x02010;HCl for pH&#x02009;2.0&#x02013;3.0, 0.1&#x02009;M citrate buffer for pH&#x02009;4.0&#x02013;6.0 and 0.1&#x02009;M sodium phosphate buffer for pH&#x02009;7.0). After incubation for 30&#x02009;min, the samples were centrifugated, filtrated, and analysed by HPLC to determine the amount of compound in solution. Stability at 25&#x000b0;C for 24&#x02009;h was determined at pH&#x02009;2.0&#x02013;7.0. The photostability towards artificial light and thermostability at 40&#x000b0;C of NOS&#x02010;G powder were examined over a period of 10&#x02009;days, with NOS as a control, whereby HPLC was applied to determine the residual amounts of NOS and NOS&#x02010;G.</p></sec><sec id="mbt214332-sec-0015"><title>
<italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> antibacterial activity of NOS&#x02010;G</title><p>Ten strains each of the bacterial pathogens, MRSA, MRSE, <italic toggle="yes">Enterococcus faecium</italic> and <italic toggle="yes">Enterococcus faecalis</italic>, were used in <italic toggle="yes">in vitro</italic> antibacterial activity tests that were performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. The tested concentrations of NOS, vancomycin and NOS&#x02010;G were 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125, 0.0156, 0.0078 and 0.0039&#x02009;&#x003bc;g/mL. The lowest concentration resulting in absence of bacterial growth was determined as the MIC of each compound.</p><p>A murine model of intraperitoneal infection was used to test the <italic toggle="yes">in vivo</italic> activity of NOS and NOS&#x02010;G. The compounds were dissolved in saline containing 10% DMSO for application. ICR mice weighing 20&#x02009;&#x000b1;&#x02009;2&#x02009;g (male and female equivalent) were injected with 0.5&#x02009;mL 2&#x02009;&#x000d7;&#x02009;10<sup>9</sup>&#x02009;CFU/mL MRSA solution. After 1&#x02010;h, a single dose of NOS or NOS&#x02010;G solution containing 2.5, 5.0 or 10&#x02009;mg/kg was administered by caudal intravenous injection. Mortality was recorded within 55&#x02009;h after treatment. The experiments were carried out with permission of the Pharmacy Animal Experiment Centre of China Pharmaceutical University.</p></sec></sec><sec id="mbt214332-sec-0016"><title>RESULTS AND DISCUSSION</title><sec id="mbt214332-sec-0017"><title>Screening of a suitable glycosyltransferase for the glycosylation of NOS</title><p>In order to identify a suitable glycosyltransferase for site&#x02010;specific glycosylation of the 3&#x02010;hydroxypyridine group of NOS, we identified 23 enzymes (glycosyltransferases and glycosynthases) from different origins (Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S2</xref>) that were heuristically selected to conduct transglycosylation of NOS, regardless of their stereo&#x02010; and site&#x02010;selectivity. These enzymes were expressed in <italic toggle="yes">E. coli</italic> with the parameters provided in Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S3</xref>, resulting in 17 soluble glycosyltransferases (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S1</xref>A,B) or glycosynthases (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S1</xref>A,C). Their activity in cell&#x02010;free extracts to glycosylate NOS using UDP&#x02010;glucose as the sugar donor was assessed, with reaction conditions summarized in Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S4</xref>. By means of LC&#x02010;MS analysis, we found that only OleD, a well&#x02010;studied GT1 family glycosyltransferase from <italic toggle="yes">S. antibioticus</italic> (Bolam et al.,&#x000a0;<xref rid="mbt214332-bib-0003" ref-type="bibr">2007</xref>; Gantt et al.,&#x000a0;<xref rid="mbt214332-bib-0007" ref-type="bibr">2013</xref>; Hughes et al.,&#x000a0;<xref rid="mbt214332-bib-0011" ref-type="bibr">2020</xref>; Zhou et al.,&#x000a0;<xref rid="mbt214332-bib-0037" ref-type="bibr">2013</xref>), produced a new compound. This product displayed a higher hydrophilicity than NOS (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S2</xref>A) with an [M+H]<sup>+</sup> value of 1384.35 (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S2</xref>B), implying that NOS had been glycosylated. After upscaling the reaction and semi&#x02010;preparative chromatographic purification, 8.9&#x02009;mg of this product was obtained with a purity over 96%. A series of NMR analyses was performed that structurally identified this product as a monoglycosyl derivative of NOS (named NOS&#x02010;G). It contained a newly&#x02010;formed &#x003b2;&#x02010;O&#x02010;glycosidic bond that linked C1 of glucose with the hydroxyl group of 3&#x02010;hydroxypyridine in NOS (Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S8</xref>). Thus, the site&#x02010;selective modification of 3&#x02010;hydroxypyridine in NOS had been successful, but the production rate of NOS&#x02010;G was still lower than 1% after optimizing the reaction system. To improve yields, OleD had to be engineered to improve its glycosylation efficiency of NOS.</p></sec><sec id="mbt214332-sec-0018"><title>Rational selection of fragments to prepare chimeric OleD</title><p>In addition to random or site&#x02010;mutagenesis strategies, swapping functional domains through recombination in a (semi&#x02010;) rational manner can be an effective way to improve the catalytic characteristics of an enzyme, as was shown for improving substrate specificity, catalytic efficiency, or operational stability (Krauth et al.,&#x000a0;<xref rid="mbt214332-bib-0016" ref-type="bibr">2009</xref>; Liang et al.,&#x000a0;<xref rid="mbt214332-bib-0018" ref-type="bibr">2015</xref>). The 3D structure of glycosyltransferase OleD from <italic toggle="yes">S. antibioticus</italic> contains a large &#x0201c;open&#x0201d; active centre, formed by functionally independent N&#x02010; and C&#x02010;terminal domains linked via a short flexible segment (Bolam et al.,&#x000a0;<xref rid="mbt214332-bib-0003" ref-type="bibr">2007</xref>). These characteristics led us to improve the catalytic efficiency of OleD for biosynthesis of NOS&#x02010;G by employing a domain&#x02010;swapping approach, even though this method has seldom been used to modify glycosyltransferases.</p><p>A high similarity of amino acid sequences between two parent enzymes is critical to obtain a functional glycosyltransferase chimera (Krauth et al.,&#x000a0;<xref rid="mbt214332-bib-0016" ref-type="bibr">2009</xref>; Weis et al.,&#x000a0;<xref rid="mbt214332-bib-0027" ref-type="bibr">2008</xref>), because it contributes to maintain the structural topology of the enzyme. Based on this, we selected <italic toggle="yes">S. antibioticus</italic> glycosyltransferase OleI, which has a similar glycosylation activity as OleD towards diverse macrolides (Bolam et al.,&#x000a0;<xref rid="mbt214332-bib-0003" ref-type="bibr">2007</xref>), to act as the donor for domain replacement of OleD. OleI exhibited over 45% amino acid (aa) sequence identity compared to OleD. We named the methodology of domain replacement between closely related enzymes with similar functions OFREDS, short for Origin and Function&#x02010;Related Enzyme Domain Swapping. After a comparative analysis of the amino acid sequences and 3D structures of both enzymes (Bolam et al.,&#x000a0;<xref rid="mbt214332-bib-0003" ref-type="bibr">2007</xref>), six regions with distinct differences were identified which we focused on to be exchanged (Figure&#x000a0;<xref rid="mbt214332-fig-0002" ref-type="fig">2A</xref>). Region 1 (aa 1&#x02013;5 in OleD and 1&#x02013;10 in OleI) at the N&#x02010;terminal and Region 2 (aa 403&#x02013;415 in OleD but missing in OleI) located at the C&#x02010;terminal without resolved X&#x02010;ray structures were predicted to be related to the stability of the enzymes (Figure&#x000a0;<xref rid="mbt214332-fig-0002" ref-type="fig">2B</xref>). Regions 3 (aa 65&#x02013;84 in OleD and aa 70&#x02013;89 in OleI) and 5 (aa 326&#x02013;340 in OleD and aa 346&#x02013;362 in OleI) contained major structural differences in the binding sites of the sugar acceptor domain, which might contribute to substrate affinity and specificity of the glycosyltransferases. The strongly different <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">m</italic>
</sub> values of OleD and OleI towards UDP&#x02010;glucose led us to also exchange the PSPG motif in region 4 (aa 282&#x02013;319 in OleD and 304&#x02013;341 in OleI), although this motif is highly conserved in UDP&#x02010;glycosyltransferases for the binding of UDP&#x02010;sugar (Zhang, Yi, et al.,&#x000a0;<xref rid="mbt214332-bib-0033" ref-type="bibr">2022</xref>). Lastly, an extensive difference in the N&#x02010;terminal sequence of region 6 was noted (missing in OleD and aa163&#x02013;181 in OleI) (Figure&#x000a0;<xref rid="mbt214332-fig-0002" ref-type="fig">2B</xref>) and this domain might be important for the catalytic efficiency of both OleD and OleI.</p><fig position="float" fig-type="FIGURE" id="mbt214332-fig-0002"><label>FIGURE 2</label><caption><p>Comparison of OleD and OleI amino acid sequences and 3D structures. (A) Amino acid sequence alignment and secondary structure prediction of OleD and OleI. Sequence identity (76%) is shaded light yellow, and similarity (90%) is green. The predicted secondary structures are indicated by a brown arrow for &#x003b2;&#x02010;sheets and green wavy lines for &#x003b1;&#x02010;helices. The six regions selected for OFREDS are presented in brackets. (B) Selected regions for OFREDS displayed in the crystal structure of OleD and OleI. Regions 1 and 2 in OleD could not be crystallized and resolved, whereas fragment 1&#x02032;, corresponding to Region 1 in OleD, was absent in OleI.</p></caption><graphic xlink:href="MBT2-16-1971-g007" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="mbt214332-sec-0019"><title>Construction and verification of OleD&#x02010;Chimeras by OFREDS</title><p>As a first step to construct chimeric enzymes by OFREDS, single replacement of each of the abovementioned six regions was conducted. This produced six first&#x02010;generation (G1) chimeric variants, called OleD&#x02010;1 to OleD&#x02010;6 (Figure&#x000a0;<xref rid="mbt214332-fig-0003" ref-type="fig">3A</xref>). After their expression in <italic toggle="yes">E. coli</italic> and partial purification by Ni<sup>2+</sup> affinity chromatography (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S3</xref>), their catalytic activity towards NOS was determined. As shown in Figure&#x000a0;<xref rid="mbt214332-fig-0003" ref-type="fig">3B</xref>, OleD&#x02010;1 and OleD&#x02010;2 resulted in a slight increase of NOS&#x02010;G production, by 5.4&#x02010; and 4.8&#x02010;folds, respectively, indicating that the swapping of region 1 at the N&#x02010;terminal or the deletion of region 2 at the C&#x02010;terminal of OleD were both beneficial for site&#x02010;specific monoglycosylation of NOS. Higher yields of NOS&#x02010;G were obtained with the chimeras OleD&#x02010;3 and OleD&#x02010;4, demonstrating that the introduction of either region 3 or 4 derived from OleI into OleD contributed to a favourable binding mode of NOS and UDP&#x02010;glucose for the enzymic reaction. In contrast, OleD&#x02010;5 and OleD&#x02010;6 lost the capability of glycosylating NOS, indicating a loss of function when these OleI&#x02010;derived sequences were introduced into OleD.</p><fig position="float" fig-type="FIGURE" id="mbt214332-fig-0003"><label>FIGURE 3</label><caption><p>Construction of OleD chimeras by OFREDS and their catalytic activities. (A) Schematic representation of parent OleD, OleI and the generated chimeras. The introduced recombination points are given by their equivalent amino acid position obtained by sequence alignment as per Figure&#x000a0;<xref rid="mbt214332-fig-0002" ref-type="fig">2A</xref>. G1 chimeras were generated by individually replacing fragments 1&#x02013;6 in OleD using corresponding regions 1&#x02032;&#x02013;6&#x02032; from OleI. G2 chimeras contained multi&#x02010;fragment replacements of OleD with 1&#x02032;&#x02013;4&#x02032; segments from OleI. (B) Relative catalytic activity of OleD chimeras towards NOS. The relative activity was calculated as the ratio <italic toggle="yes">A</italic>
<sub>
<italic toggle="yes">V</italic>
</sub>/<italic toggle="yes">A</italic>
<sub>OleD</sub>, where <italic toggle="yes">A</italic>
<sub>
<italic toggle="yes">V</italic>
</sub> and <italic toggle="yes">A</italic>
<sub>OleD</sub> are the production rate of NOS&#x02010;G produced by the chimeras and OleD, respectively.</p></caption><graphic xlink:href="MBT2-16-1971-g006" position="anchor" id="jats-graphic-7"/></fig><p>In a next step, combinational domain swapping was applied, involving the four favourable regions verified above. This created the second&#x02010;generation (G2) OleD chimeras as displayed in Figure&#x000a0;<xref rid="mbt214332-fig-0003" ref-type="fig">3A</xref>. Compared to the G1 products, all G2 chimeras, which contained two or more OleI&#x02010;originating domains, displayed increased activity towards NOS, at different levels. In particular OleD&#x02010;10 was highly active, resulting in a 38&#x02010;fold increase compared to wild&#x02010;type OleD (Figure&#x000a0;<xref rid="mbt214332-fig-0003" ref-type="fig">3B</xref>). This was due to combined introduction of regions 1, 2, 3 and 4 from OleI, which were compatible and produced a highly efficient chimeric enzyme. Such a contribution of four positive motifs acting in combination has been seldomly observed in domain&#x02010;swapping examples of glycosyltransferases (Krauth et al.,&#x000a0;<xref rid="mbt214332-bib-0016" ref-type="bibr">2009</xref>; Weis et al.,&#x000a0;<xref rid="mbt214332-bib-0027" ref-type="bibr">2008</xref>). Although OleD&#x02010;10 increased the production rate of NOS&#x02010;G from 0.8% (wild&#x02010;type OleD) to 30.4%, we needed to further enhance its site&#x02010;specific monoglycosylation activity in order to prepare sufficient NOS&#x02010;G amounts for in vivo anti&#x02010;pathogenic assays.</p></sec><sec id="mbt214332-sec-0020"><title>Establishment of a colorimetric method for glycosyltransferase screening</title><p>To produce NOS&#x02010;G at higher yields, multiple mutants of chimeric OleD&#x02010;10 had to be screened for enhanced monoglycosylation activity, for which the product identification by HPLC was unpractical. Moreover, a reaction system containing crude cell extracts of expressed OleD&#x02010;10 mutants excluded the practical utility of existing UGTs screening strategies that depend on purified enzyme, such as a pH indicator assay and a fluorescence&#x02010;based assay (Hewitt et al.,&#x000a0;<xref rid="mbt214332-bib-0010" ref-type="bibr">2019</xref>; Persson &#x00026; Palcic,&#x000a0;<xref rid="mbt214332-bib-0022" ref-type="bibr">2008</xref>; Ryu et al.,&#x000a0;<xref rid="mbt214332-bib-0023" ref-type="bibr">2014</xref>). To overcome this, we first considered the high&#x02010;throughput screening method of a dual GT coupled reaction (DGCR) (Williams et al.,&#x000a0;<xref rid="mbt214332-bib-0028" ref-type="bibr">2007</xref>) for screening OleD&#x02010;10 variants in a colorimetric assay. Unfortunately, the overlap in absorption wavelength and colour between NOS and the indicator product, 2&#x02010;chloro&#x02010;4&#x02010;nitrophenolate, prevented its application. We have previously described that sucrose synthase <italic toggle="yes">At</italic>SUS (GenBank accession number OAP16120.1) from <italic toggle="yes">Arabidopsis thaliana</italic> catalyses the reversible conversion of sucrose and uridine diphosphate (UDP) into UDP&#x02010;glucose (UDPG) and reductive fructose (Zhang, Xu, et al.,&#x000a0;<xref rid="mbt214332-bib-0035" ref-type="bibr">2020</xref>). By coupling with OleD&#x02010;10 variants, <italic toggle="yes">At</italic>SUS&#x02010;generated UDPG could serve as a sugar donor to monoglycosylate NOS for the biosynthesis of NOS&#x02010;G. The catalytic activity of an OleD&#x02010;10 variant towards NOS was then indirectly determined by colourizing simultaneously produced fructose using DNS reagent (Figure&#x000a0;<xref rid="mbt214332-fig-0004" ref-type="fig">4</xref>). This OleD&#x02010;<italic toggle="yes">At</italic>SUS colorimetric screening method (OACSM) was used for the screening of OleD&#x02010;10 variants. The method not only allowed rapid screening of multiple OleD&#x02010;10 variants but was also cost&#x02010;effective, as it did not require UDP&#x02010;glucose to be added.</p><fig position="float" fig-type="FIGURE" id="mbt214332-fig-0004"><label>FIGURE 4</label><caption><p>OACSM for semi&#x02010;high throughput screening of OleD variants. A UDP&#x02010;UDPG regeneration system was constructed by combining the activity of AtSUS and OleD variants. AtSUS produced UDP&#x02010;glucose and fructose from sucrose and UDP. The formed UDP&#x02010;glucose was consumed by an OleD variant to produce NOS&#x02010;G as the rate&#x02010;limiting step, while the concentration of fructose was determined by DNS colorimetry in a 96&#x02010;well plate. The absorbance was measured at 540&#x02009;nm against a blank.</p></caption><graphic xlink:href="MBT2-16-1971-g003" position="anchor" id="jats-graphic-9"/></fig><p>Any possible endogenous interference in <italic toggle="yes">E. coli</italic> BL21(DE3) was considered first, for which a KEGG analysis was carried out according to reported methods (Kanehisa et al.,&#x000a0;<xref rid="mbt214332-bib-0013" ref-type="bibr">2017</xref>). This identified maltodextrin glucosidase (MalZ) in the sugar metabolic pathway of <italic toggle="yes">E. coli</italic> BL21(DE3) (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S4</xref>A) that is able to convert sucrose to fructose and glucose (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S4</xref>B) (Dippel &#x00026; Boos,&#x000a0;<xref rid="mbt214332-bib-0004" ref-type="bibr">2005</xref>), which would hamper the accuracy of our designed OACSM. To correct for this, the <italic toggle="yes">malZ</italic> gene was knocked out to create <italic toggle="yes">E. coli malZ</italic>
<sup>&#x02013;</sup>KO in which the endogenous production of fructose was decreased by 91.6% compared with wild&#x02010;type <italic toggle="yes">E. coli</italic> BL21(DE3) (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S5</xref>A,B). This satisfactory removal of the background fructose synthesis allowed screening of OleD&#x02010;10 variants by OACSM after expression in <italic toggle="yes">E. coli malZ</italic>
<sup>&#x02013;</sup>KO. The obtained data (Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S9</xref>) demonstrated a wide range of substrate linearity between 0.05 and 0.80&#x02009;mM of fructose, and a recovery rate of 99.96% with a precision of 0.969 was obtained. The limit of detection (LoD) was 0.041&#x02009;mM and the limit of quantitation (LoQ) was 0.123&#x02009;mM. Importantly, the brown colour and A<sub>540</sub> indicative of a positive reaction with detectable fructose remained unchanged after 2&#x02009;h at room temperature (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S5</xref>B), suggesting that this colorimetric system was suitable for application. We therefore applied OACSM for rapid screening of OleD&#x02010;10 variants.</p></sec><sec id="mbt214332-sec-0021"><title>Semi&#x02010;rational engineering of chimeric OleD&#x02010;10</title><p>In order to determine the most suitable sites for further optimizing OleD&#x02010;10, we first confirmed the catalytic site of the enzyme. In accordance with the described glycosylation mechanism of OleD (Bolam et al.,&#x000a0;<xref rid="mbt214332-bib-0003" ref-type="bibr">2007</xref>; Gantt et al.,&#x000a0;<xref rid="mbt214332-bib-0007" ref-type="bibr">2013</xref>), site&#x02010;directed mutagenesis (results not shown) confirmed that its catalytic site consists of the dyad H25&#x02010;D116, in which H25 directly removes a proton from the hydroxyl of NOS, to nucleophilically attack the active C1 of glucose in the UDP&#x02010;sugar (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S6</xref>A). This is based on the docking complex of NOS and the crystal structure of chimeric OleD&#x02010;10 containing UDPG (PDB ID: 7XX4) (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S6</xref>B). In accordance with a reported example (Xu et al.,&#x000a0;<xref rid="mbt214332-bib-0031" ref-type="bibr">2022</xref>), we then selected target mutation sites in OleD&#x02010;10 for activity enhancement within 4&#x02009;&#x000c5; around residue H25; these were S2, I20, A22, H23, G24, V26, N27, P28, W79, D116, T118 and P138 (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S7</xref>A). The amino acids in the 4&#x02009;&#x000c5; range around NOS were also considered: W79, P80, E81, M87, F90, I117, T118, Y120, P138, N139, L140, Y146, E149, V150, M154, A188S, M314 and D335 (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S7</xref>B). Combining all sites and after removal of duplicate sites and exclusion of catalytic D116, a total of 26 residues in OleD&#x02010;10 were used for site&#x02010;directed mutagenesis by replacing them with alanine or serine (Figure&#x000a0;<xref rid="mbt214332-fig-0005" ref-type="fig">5A,B</xref>). Increased activity was found for variants I117A and T118A (Figure&#x000a0;<xref rid="mbt214332-fig-0005" ref-type="fig">5B</xref>) which exhibited 1.11 and 1.16 times higher activity, respectively, of NOS&#x02010;G production compared to OleD&#x02010;10. An absolute loss of activity was observed for mutants N139A, M314A and D335A. This suggests that these five sites are important for the glycosylation of NOS, and amino acid substitution at these sites may dramatically change OleD&#x02010;10 structures or substrate&#x02010;enzyme interaction modes. We then performed saturation mutagenesis for I117, T118, N139, M314 and D335 to create variants with improved activity towards NOS.</p><fig position="float" fig-type="FIGURE" id="mbt214332-fig-0005"><label>FIGURE 5</label><caption><p>Workflow for optimizing the activity of glycosyltransferase OleD towards NOS. (A) Schematic of the iterative mutagenesis pathway of OleD for activity improvement. The numbers above the horizontal lines show the relative activity of OleD variants compared with OleD. (B) Relative activity of alanine&#x02010;scanning variants of OleD&#x02010;10. The distinguished variants in activity compared to OleD&#x02010;10 are marked in brown. (C) The relative activity of OleD&#x02010;10 variants by saturation mutagenesis at I117. The four variants with the highest activity (I117A/F/W/S) are shown in orange. (D) The relative activity of OleD&#x02010;10 variants by saturation mutagenesis at T118. The best&#x02010;performing variants (T118G/K/Q/H) are shown in yellow. (E) Relative activity of double mutants of OleD&#x02010;10. The best variant, combining I117F with T118G (FG), is marked in pink. For all groups, error bars represent the standard deviation from three replicates. The relative activity of all variants was calculated according to Figure&#x000a0;<xref rid="mbt214332-fig-0003" ref-type="fig">3B</xref>.</p></caption><graphic xlink:href="MBT2-16-1971-g002" position="anchor" id="jats-graphic-11"/></fig><p>By application of OACSM, all produced variants were screened and their activity was compared to OleD&#x02010;10, and promising candidates were confirmed by HPLC. As shown in Figure&#x000a0;<xref rid="mbt214332-fig-0005" ref-type="fig">5C,D</xref>, the replacement of I117 to A, F, W and S and of T118 to G, K, Q and H, all increased the production rate of NOS&#x02010;G by at least 10% and 20%. However, residue substitution of N139, M314 and D335 did not significantly alter activity for monoglycosylation of NOS (data not shown). Subsequently, synergistic effects of I117X<sub>1</sub> (<italic toggle="yes">X</italic>
<sub>1</sub>&#x02009;=&#x02009;A, F, W) and T118X<sub>2</sub> (<italic toggle="yes">X</italic>
<sub>2</sub>&#x02009;=&#x02009;G, K, Q, H) were explored by combinatorial mutagenesis. The combination I117F/T118G (abbreviated as FG) resulted in the best&#x02010;performing OleD&#x02010;10 double&#x02010;mutant, with a NOS&#x02010;G production of 56%, almost 70&#x02010;fold higher than wild&#x02010;type OleD (Figure&#x000a0;<xref rid="mbt214332-fig-0005" ref-type="fig">5A,E</xref>). The incomplete conversion of NOS to NOS&#x02010;G was supposed to be caused by an insoluble form of NOS in the reaction mixture, as a granular deposit was formed over time. For this reason, further enzyme optimization was not performed. The insolubility of NOS in various organic solvents (Xie et al.,&#x000a0;<xref rid="mbt214332-bib-0030" ref-type="bibr">2019</xref>) also hampered the possibility of constructing a biphasic reaction system using aqueous buffer and an immiscible solvent (Zhang, Bittner, et al.,&#x000a0;<xref rid="mbt214332-bib-0034" ref-type="bibr">2022</xref>) for FG&#x02010;catalysed monoglycosylation. Nevertheless, the produced chimeric FG was sufficiently active to produce NOS&#x02010;G amounts required for in vivo tests.</p></sec><sec id="mbt214332-sec-0022"><title>Molecular basis of enhanced glycosylation activity of chimeric OleD variants</title><p>To investigate the molecular basis for the enhanced activity of the engineered OleD&#x02010;10 enzyme, first the crystal structure of the protein&#x02010;UDPG complex (PDB ID: 7XX4) was solved for the chimeric OleD&#x02010;10 protein prior to site&#x02010;specific modification. For this, X&#x02010;ray crystallography was performed at a resolution of 2.5&#x02009;&#x000c5;, characterized by the diffraction refinement and statistical data shown in Table&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S10</xref>. As shown in Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S8</xref>A,B, the chimeric OleD&#x02010;10 protein belongs to the conserved GT&#x02010;B fold just like wild&#x02010;type OleD (Bolam et al.,&#x000a0;<xref rid="mbt214332-bib-0003" ref-type="bibr">2007</xref>), in which the characteristic &#x003b2;/&#x003b1;/&#x003b2; Rossman fold was composed of the N&#x02010;terminal region with six &#x003b1;&#x02010;helices and seven &#x003b2;&#x02010;strands (M1&#x02010;G218 and G290&#x02010;A405), the C&#x02010;terminal region containing six &#x003b1;&#x02010;helices and six &#x003b2;&#x02010;strands (D223&#x02010;A405) and a flexible loop linking the two regions. When the structural diagrams of OleD and OleD&#x02010;10 were superpositioned, it displayed that the overall structure of OleD&#x02010;10 is much tighter than that of OleD (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S8</xref>C). In crystalline OleD&#x02010;10 formed in presence of UDPG, the distance of UDPG (determined by the C1 position of the sugar unit) was positioned close to catalytic residue H25, at 6.00&#x02009;&#x000c5; distance (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S8</xref>D). In contrast, the distance between UDPG and catalytic H19 of wild&#x02010;type OleD (corresponding to H25 in OleD&#x02010;10) was much longer, at 13.61&#x02009;&#x000c5; (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S8</xref>E). This difference in the structure of OleD&#x02010;10 would favourably facilitate the SN<sub>2</sub>&#x02010;like nucleophilic attack of de&#x02010;protonated 3&#x02010;OH of the pyridine group in NOS against the C1 of glucose in UDPG (Bolam et al.,&#x000a0;<xref rid="mbt214332-bib-0003" ref-type="bibr">2007</xref>; Nidetzky et al.,&#x000a0;<xref rid="mbt214332-bib-0021" ref-type="bibr">2018</xref>). In addition, we performed a 200&#x02009;ns molecular dynamic (MD) simulation (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S9</xref>A,B), which indicated that the non&#x02010;touching state of NOS and UDPG in catalytic OleD (Figure&#x000a0;<xref rid="mbt214332-fig-0006" ref-type="fig">6A</xref>) was probably the main factor resulting in a negligible efficiency to produce NOS&#x02010;G by this enzyme, with <italic toggle="yes">k</italic>
<sub>cat</sub>/<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">m</italic>
</sub> at 0.01&#x02009;mM/s (Table&#x000a0;<xref rid="mbt214332-tbl-0001" ref-type="table">1</xref>). In the chimeric OleD&#x02010;10 simulation, two detached substrates, NOS and UDPG, were closer in stereo space (Figure&#x000a0;<xref rid="mbt214332-fig-0006" ref-type="fig">6B</xref>).</p><fig position="float" fig-type="FIGURE" id="mbt214332-fig-0006"><label>FIGURE 6</label><caption><p>Catalytic conformations of OleD, chimeric OleD&#x02010;10 and FG. (A) Catalytic conformation of OleD docked with NOS and UDPG. (B) Catalytic conformation of OleD&#x02010;10 containing NOS and UDPG. The surfaces of both enzymes are depicted in light grey. The NOS and UDPG are denoted by clumps coloured in yellow and blue, respectively. (C) Binding conformation of NOS and UDPG in OleD&#x02010;10. (D) Binding conformation of NOS and UDPG in FG. The red dashed line displays the distance between H25 and O of 3&#x02010;hydroxypyridine in NOS. The distance between that O and C1 of the glucose in UDPG is marked in yellow.</p></caption><graphic xlink:href="MBT2-16-1971-g008" position="anchor" id="jats-graphic-13"/></fig><table-wrap position="float" id="mbt214332-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Kinetic parameters for OleD and its improved variants.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Enzyme</th><th align="left" valign="bottom" rowspan="1" colspan="1">Substrate</th><th align="left" valign="bottom" rowspan="1" colspan="1">Apparent <italic toggle="yes">k</italic>
<sub>cat</sub> (s<sup>&#x02212;1</sup>)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Apparent <italic toggle="yes">K</italic>
<sub>m</sub> (mM)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Apparent <italic toggle="yes">V</italic>
<sub>max</sub> (mmol/min/mg)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Apparent <italic toggle="yes">k</italic>
<sub>cat</sub>/<italic toggle="yes">K</italic>
<sub>m</sub> (mM/s)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">FG</td><td align="left" rowspan="3" valign="top" colspan="1">NOS</td><td align="left" valign="top" rowspan="1" colspan="1">0.32&#x02009;&#x000b1;&#x02009;0.07</td><td align="left" valign="top" rowspan="1" colspan="1">0.52&#x02009;&#x000b1;&#x02009;0.09</td><td align="left" valign="top" rowspan="1" colspan="1">11.16&#x02009;&#x000b1;&#x02009;1.43</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OleD&#x02010;10</td><td align="left" valign="top" rowspan="1" colspan="1">0.16&#x02009;&#x000b1;&#x02009;0.09</td><td align="left" valign="top" rowspan="1" colspan="1">0.72&#x02009;&#x000b1;&#x02009;0.13</td><td align="left" valign="top" rowspan="1" colspan="1">9.64&#x02009;&#x000b1;&#x02009;1.72</td><td align="left" valign="top" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OleD</td><td align="left" valign="top" rowspan="1" colspan="1">0.01&#x02009;&#x000b1;&#x02009;0.01</td><td align="left" valign="top" rowspan="1" colspan="1">0.98&#x02009;&#x000b1;&#x02009;0.11</td><td align="left" valign="top" rowspan="1" colspan="1">4.66&#x02009;&#x000b1;&#x02009;0.15</td><td align="left" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FG</td><td align="left" rowspan="3" valign="top" colspan="1">UDPG</td><td align="left" valign="top" rowspan="1" colspan="1">0.27&#x02009;&#x000b1;&#x02009;0.08</td><td align="left" valign="top" rowspan="1" colspan="1">1.64&#x02009;&#x000b1;&#x02009;0.15</td><td align="left" valign="top" rowspan="1" colspan="1">12.10&#x02009;&#x000b1;&#x02009;0.22</td><td align="left" valign="top" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OleD&#x02010;10</td><td align="left" valign="top" rowspan="1" colspan="1">0.14&#x02009;&#x000b1;&#x02009;0.04</td><td align="left" valign="top" rowspan="1" colspan="1">2.93&#x02009;&#x000b1;&#x02009;0.25</td><td align="left" valign="top" rowspan="1" colspan="1">8.15&#x02009;&#x000b1;&#x02009;0.17</td><td align="left" valign="top" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OleD</td><td align="left" valign="top" rowspan="1" colspan="1">n.a.</td><td align="left" valign="top" rowspan="1" colspan="1">n.a.</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot id="mbt214332-ntgp-0101"><fn id="mbt214332-note-0001"><p>Abbreviation: n.a., not available.</p></fn></table-wrap-foot></table-wrap><p>To gain insight into the molecular basis of improved NOS glycosylation activity by OleD&#x02010;10 and FG, we modelled the flexible docking of NOS and UDPG with FG, using the OleD&#x02010;10 structure as a template, as well as a 200&#x02009;ns MD simulation of the resulting complex (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S9</xref>C). The steady&#x02010;state conformation of FG was obtained with a distance &#x0003c;3&#x02009;&#x000c5; between the 3&#x02010;hydroxy&#x02010;O of the core pyridine in NOS for SN<sub>2</sub>&#x02010;like transglycosylation (Bolam et al.,&#x000a0;<xref rid="mbt214332-bib-0003" ref-type="bibr">2007</xref>; Nidetzky et al.,&#x000a0;<xref rid="mbt214332-bib-0021" ref-type="bibr">2018</xref>) and the NE2 nitrogen of the catalytic residue H25. That distance is much lower than that observed with OleD&#x02010;10 (Figure&#x000a0;<xref rid="mbt214332-fig-0006" ref-type="fig">6C,D</xref>), suggesting that the combined substitutions of I117F and T118G had further enhanced the enzyme&#x02010;substrate binding affinity. This was confirmed by the kinetic parameters in Table&#x000a0;<xref rid="mbt214332-tbl-0001" ref-type="table">1</xref>, listing the apparent <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">m</italic>
</sub> values of 0.52&#x02009;mM for FG towards NOS and 1.64&#x02009;mM towards UDP&#x02010;glucose. Correspondingly, the apparent <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">m</italic>
</sub> values for OleD&#x02010;10 were both enhanced to 0.72 and 2.93&#x02009;mM, respectively. In addition, the calculated binding free energies for NOS in OleD&#x02010;10 (&#x02212;145.21&#x02009;kJ/mol) and in variant FG (&#x02212;210.99&#x02009;kJ/mol) were also in line with its improved activity towards NOS.</p><p>According to the established root mean square deviation (RMSD), the conformations of the two enzymes OleD&#x02010;10 and FG with their NOS and UDPG substrates were stable after 100&#x02009;ns of MD simulation (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S9</xref>C). Compared to OleD&#x02010;10, the lower RMSD value of variant FG suggested the formation of a more stable complex of enzyme and substrates, which guaranteed a better activity towards NOS with a 2.8&#x02010;fold increase in catalytic efficiency (Table&#x000a0;<xref rid="mbt214332-tbl-0001" ref-type="table">1</xref>). Most of the amino acids located around the catalytic pocket in variant FG produced lower root mean square fluctuation (RMSF) values than their corresponding equivalents in OleD&#x02010;10 (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S9</xref>D), again indicating the superior binding of substrate in FG that would result in higher reaction rates (Li et al.,&#x000a0;<xref rid="mbt214332-bib-0017" ref-type="bibr">2020</xref>).</p></sec><sec id="mbt214332-sec-0023"><title>Physicochemical properties and biological activity of NOS&#x02010;G</title><p>To determine the effect of the glycosylation of NOS on the properties of the compound, the solubility and stability were investigated for a pH range of 2.0 to 7.0. As shown in Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S10</xref>A, NOS&#x02010;G displayed a remarkably enhanced solubility in water at all tested pH values compared to NOS. It reached the highest concentration of 596.2&#x02009;ng/mL at pH&#x02009;6.0, which was approximately 21&#x02010;fold higher than NOS (28.3&#x02009;ng/mL) at that pH. Both NOS&#x02010;G and NOS were stable in acidic solutions for 24&#x02009;h in the dark (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S10</xref>B). The shelf&#x02010;life of NOS&#x02010;G powder was good: storage at &#x02212;20&#x000b0;C for 12&#x02009;months resulted in negligible chemical degradation (data not shown). Exposed to light, thermostability of NOS&#x02010;G powder was tested at 40&#x000b0;C at which temperature it was quite stable: after 10&#x02009;days a decrease of only 1.5% was noted, whereas NOS was somewhat less stable, leading to a 4% decrease on day 10 (Figure&#x000a0;<xref rid="mbt214332-supitem-0001" ref-type="supplementary-material">S10</xref>C). Thus, glycosylation had improved physicochemical properties of NOS in terms of stability and solvability, which are important contributors for druggability.</p><p>Next, the antibacterial activity of NOS&#x02010;G was tested <italic toggle="yes">in vitro</italic>. As shown in Table&#x000a0;<xref rid="mbt214332-tbl-0002" ref-type="table">2</xref>, <italic toggle="yes">in vitro</italic> anti&#x02010;bacterial activity was detected against strains of MRSA, MRSE, <italic toggle="yes">Enterococcus faecalis</italic> and <italic toggle="yes">Enterococcus faecium</italic>, with MIC values ranging from 0.0625 to 0.5&#x02009;&#x003bc;g/mL, which was only slightly higher than the values for NOS, but significantly better than vancomycin. This implied that the 3&#x02010;hydroxy group of the core pyridine group of NOS could be modified without loss of antibacterial activity. Lastly, the therapeutic potency of NOS&#x02010;G was assessed in an animal model. Mice were infected with MRSA and injected with a single dose of NOS or NOS&#x02010;G 1&#x02009;h post&#x02010;infection. Three doses were tested. As shown in Figure&#x000a0;<xref rid="mbt214332-fig-0007" ref-type="fig">7</xref>, administration of NOS or NOS&#x02010;G effectively delayed death of the animals. At the lowest dose tested (2.5&#x02009;mg/kg), the survival rate in the NOS&#x02010;G&#x02010;treated group was 50% at 20&#x02009;h post&#x02010;infection, which is slightly better than NOS (37.5%)&#x000a0;(Figure&#x000a0;<xref rid="mbt214332-fig-0007" ref-type="fig">7A</xref>). A higher therapeutic effect of NOS&#x02010;G became apparent at higher dosages (5 and 10&#x02009;mg/kg): at 20&#x02009;h, NOS&#x02010;G&#x02010;treated animals had a survival rate of 62.5%, while it was still 37.5% for the NOS&#x02010;treated group (Figure&#x000a0;<xref rid="mbt214332-fig-0007" ref-type="fig">7B,C</xref>). This shows that structural alteration of the 3&#x02010;hydroxyl group of the pyridine ring in NOS could bring about positive effects, which might be a potential breakthrough to overcome the inactivity of NOS in vivo in the future.</p><table-wrap position="float" id="mbt214332-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>In vitro antibacterial activity of NOS and NOS&#x02010;G (MIC in &#x003bc;g/mL).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Pathogens</th><th align="left" valign="bottom" rowspan="1" colspan="1">NOS</th><th align="left" valign="bottom" rowspan="1" colspan="1">NOS&#x02010;G</th><th align="left" valign="bottom" rowspan="1" colspan="1">Vancomycin</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">MRSE</td><td align="left" valign="top" rowspan="1" colspan="1">0.0156&#x02013;0.03125</td><td align="left" valign="top" rowspan="1" colspan="1">0.0625&#x02013;0.125</td><td align="left" valign="top" rowspan="1" colspan="1">0.25&#x02013;2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MRSA</td><td align="left" valign="top" rowspan="1" colspan="1">0.078&#x02013;0.0156</td><td align="left" valign="top" rowspan="1" colspan="1">0.0625&#x02013;0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.25&#x02013;4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Enterococcus faecalis</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.0156&#x02013;0.03125</td><td align="left" valign="top" rowspan="1" colspan="1">0.0625&#x02013;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.5&#x02013;4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Enterococcus faecium</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.078&#x02013;0.03125</td><td align="left" valign="top" rowspan="1" colspan="1">0.03125&#x02013;0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.5&#x02013;4</td></tr></tbody></table></table-wrap><fig position="float" fig-type="FIGURE" id="mbt214332-fig-0007"><label>FIGURE 7</label><caption><p>Survival curve of MRSA&#x02010;infected mice after administration of NOS and NOS&#x02010;G. (A) Survival rate of MRSA&#x02010;infected mice administered NOS or NOS&#x02010;G at a dose of 2.5&#x02009;mg/kg. (B) Survival rate of MRSA&#x02010;infected mice at a dose of 5&#x02009;mg/kg. (C) Survival rate of MRSA&#x02010;infected mice at a dose of 10&#x02009;mg/kg. The blue and red lines represent the survival rates of mice treated by NOS and NOS&#x02010;G, respectively, while the black line is an infected group administrated 6.8&#x02009;mg/kg vancomycin.</p></caption><graphic xlink:href="MBT2-16-1971-g005" position="anchor" id="jats-graphic-15"/></fig></sec></sec><sec sec-type="conclusions" id="mbt214332-sec-0024"><title>CONCLUSIONS</title><p>To identify whether modification of the 3&#x02010;hydroxyl group of the core pyridine ring in NOS was feasible, despite its presumed contribution to antibacterial activity of the compound, we glycosylated the site. For this, an enzymatic strategy was designed that allowed site&#x02010;specific modification without the formation of byproducts. The starting point was glycosyltransferase OleD that could perform the desired site&#x02010;specific glycosylation, albeit with low efficiency. Its activity was subsequently enhanced, first by single domain swapping, then by combining promising domains, and finally by site&#x02010;directed mutagenesis, again singly and in combination. The procedures were enabled by use of a semi&#x02010;high&#x02010;throughput screening method for activity. The resulting variant FG exhibiting a 70&#x02010;fold improvement in the biosynthetic activity of NOS&#x02010;G compared to OleD. This increased activity was due to a tighter structure of FG when interacting with UDPG and NOS. The shorter distance (&#x0003c;3&#x02009;&#x000c5;) of the substrate to H25 in the catalytic site to the sugar most likely contributed to a more efficient SN<sub>2</sub>&#x02010;type transglycosylation. The glycosylation of NOS improved its solubility and stability and its antibacterial activity was conserved. In addition, NOS&#x02010;G possessed a promising <italic toggle="yes">in vivo</italic> protective effect towards MRSA infection in mice. We conclude that the 3&#x02010;hydroxypyridine ring of NOS is a suitable target for modification to create novel NOS&#x02010;derived analogues with a better druggability in the future.</p></sec><sec id="mbt214332-sec-0028"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Ling Zhao:</bold> Data curation (equal); formal analysis (equal); methodology (equal); writing &#x02013; original draft (supporting). <bold>Yuncong Xu:</bold> Formal analysis (equal); methodology (equal); writing &#x02013; original draft (equal). <bold>Manting Chen:</bold> Data curation (supporting); formal analysis (equal); methodology (equal); writing &#x02013; original draft (supporting). <bold>Lingrui Wu:</bold> Data curation (supporting); methodology (supporting). <bold>Meng Li:</bold> Investigation (supporting); methodology (supporting). <bold>Yuanyuan Lu:</bold> Formal analysis (supporting). <bold>Meiling Lu:</bold> Formal analysis (equal). <bold>Yijun Chen:</bold> Conceptualization (supporting); formal analysis (equal). <bold>Xuri Wu:</bold> Conceptualization (lead); formal analysis (equal); supervision (lead); writing &#x02013; original draft (equal); writing &#x02013; review and editing (lead).</p></sec><sec sec-type="COI-statement" id="mbt214332-sec-0027"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no competing financial interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="mbt214332-supitem-0001" position="float" content-type="local-data"><caption><p>
Appendix S1.
</p></caption><media xlink:href="MBT2-16-1971-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="mbt214332-sec-0025"><title>ACKNOWLEDGEMENTS</title><p>This work was supported by National Key Research and Development Program of China (grant no. 2018YFA0902000), National Natural Science Foundation of China (grant no. 81973214), Key Research and Development Project of Guangdong Province (grant no. 2022B1111070004), the &#x0201c;Double First&#x02010;Class&#x0201d; University project (grant no. CPU2022QZ08) and the National Innovation and Entrepreneurship Training Program for Undergraduate (grant no. 202310316020Z).</p></ack><ref-list content-type="cited-references" id="mbt214332-bibl-0001"><title>REFERENCES</title><ref id="mbt214332-bib-0001"><mixed-citation publication-type="journal" id="mbt214332-cit-0001">
<string-name>
<surname>Bagley</surname>, <given-names>M.C.</given-names>
</string-name>, <string-name>
<surname>Dale</surname>, <given-names>J.W.</given-names>
</string-name>, <string-name>
<surname>Merritt</surname>, <given-names>E.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Xiong</surname>, <given-names>X.</given-names>
</string-name> (<year>2015</year>) <article-title>Thiopeptide antibiotics</article-title>. <source>Chemical Reviews</source>, <volume>105</volume>, <fpage>685</fpage>&#x02013;<lpage>714</lpage>.</mixed-citation></ref><ref id="mbt214332-bib-0002"><mixed-citation publication-type="journal" id="mbt214332-cit-0002">
<string-name>
<surname>Benazet</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Cartier</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Florent</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Godard</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Jung</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Lunel</surname>, <given-names>J.</given-names>
</string-name> et al. (<year>1980</year>) <article-title>Nosiheptide, a sulfur&#x02010;containing peptide antibiotic isolated from <italic toggle="yes">Streptomyces actuosus</italic> 40037</article-title>. <source>Experientia</source>, <volume>36</volume>, <fpage>414</fpage>&#x02013;<lpage>416</lpage>.<pub-id pub-id-type="pmid">7379912</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0003"><mixed-citation publication-type="journal" id="mbt214332-cit-0003">
<string-name>
<surname>Bolam</surname>, <given-names>D.N.</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Proctor</surname>, <given-names>M.R.</given-names>
</string-name>, <string-name>
<surname>Turkenburg</surname>, <given-names>J.P.</given-names>
</string-name>, <string-name>
<surname>Dodson</surname>, <given-names>E.J.</given-names>
</string-name>, <string-name>
<surname>Martinez&#x02010;Fleites</surname>, <given-names>C.</given-names>
</string-name> et al. (<year>2007</year>) <article-title>The crystal structure of two macrolide glycosyltransferases provides a blueprint for host cell antibiotic immunity</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>, <volume>104</volume>, <fpage>5336</fpage>&#x02013;<lpage>5341</lpage>.<pub-id pub-id-type="pmid">17376874</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0004"><mixed-citation publication-type="journal" id="mbt214332-cit-0004">
<string-name>
<surname>Dippel</surname>, <given-names>R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Boos</surname>, <given-names>W.</given-names>
</string-name> (<year>2005</year>) <article-title>The maltodextrin system of <italic toggle="yes">Escherichia coli</italic>: metabolism and transport</article-title>. <source>Journal of Bacteriology</source>, <volume>187</volume>, <fpage>8322</fpage>&#x02013;<lpage>8331</lpage>.<pub-id pub-id-type="pmid">16321936</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0005"><mixed-citation publication-type="journal" id="mbt214332-cit-0005">
<string-name>
<surname>Fan</surname>, <given-names>Y.F.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>H.F.</given-names>
</string-name>, <string-name>
<surname>Mu</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>W.G.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>K.K.</given-names>
</string-name>, <string-name>
<surname>Ruan</surname>, <given-names>Z.</given-names>
</string-name> et al. (<year>2021</year>) <article-title>Nosiheptide analogues as potential antibacterial agents via dehydroalanine region modifications: semi&#x02010;synthesis, antimicrobial activity and molecular docking study</article-title>. <source>Bioorganic &#x00026; Medicinal Chemistry</source>, <volume>31</volume>, <elocation-id>115970</elocation-id>.<pub-id pub-id-type="pmid">33422909</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0006"><mixed-citation publication-type="journal" id="mbt214332-cit-0006">
<string-name>
<surname>Fernando</surname>, <given-names>C.D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Soysa</surname>, <given-names>P.</given-names>
</string-name> (<year>2015</year>) <article-title>Optimized enzymatic colorimetric assay for determination of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) scavenging activity of plant extracts</article-title>. <source>MethodsX</source>, <volume>2</volume>, <fpage>283</fpage>&#x02013;<lpage>291</lpage>.<pub-id pub-id-type="pmid">26285798</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0007"><mixed-citation publication-type="journal" id="mbt214332-cit-0007">
<string-name>
<surname>Gantt</surname>, <given-names>R.W.</given-names>
</string-name>, <string-name>
<surname>Peltier&#x02010;Pain</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Singh</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Thorson</surname>, <given-names>J.S.</given-names>
</string-name> (<year>2013</year>) <article-title>Broadening the scope of glycosyltransferase&#x02010;catalyzed sugar nucleotide synthesis</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>, <volume>110</volume>, <fpage>7648</fpage>&#x02013;<lpage>7653</lpage>.<pub-id pub-id-type="pmid">23610417</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0008"><mixed-citation publication-type="journal" id="mbt214332-cit-0008">
<string-name>
<surname>Harms</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>, <given-names>D.N.</given-names>
</string-name>, <string-name>
<surname>Schluenzen</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Connell</surname>, <given-names>S.R.</given-names>
</string-name>, <string-name>
<surname>Stachelhaus</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Zaborowska</surname>, <given-names>Z.</given-names>
</string-name> et al. (<year>2008</year>) <article-title>Translational regulation via L11: molecular switches on the ribosome turned on and off by thiostrepton and micrococcin</article-title>. <source>Molecular Cell</source>, <volume>30</volume>, <fpage>26</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">18406324</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0009"><mixed-citation publication-type="journal" id="mbt214332-cit-0009">
<string-name>
<surname>Haste</surname>, <given-names>N.M.</given-names>
</string-name>, <string-name>
<surname>Thienphrapa</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Tran</surname>, <given-names>D.N.</given-names>
</string-name>, <string-name>
<surname>Loesgen</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Nam</surname>, <given-names>S.J.</given-names>
</string-name> et al. (<year>2012</year>) <article-title>Activity of the thiopeptide antibiotic nosiheptide against contemporary strains of methicillin&#x02010;resistant <italic toggle="yes">Staphylococcus aureus</italic>
</article-title>. <source>Journal of Antibiotics (Tokyo)</source>, <volume>65</volume>, <fpage>593</fpage>&#x02013;<lpage>598</lpage>.</mixed-citation></ref><ref id="mbt214332-bib-0010"><mixed-citation publication-type="journal" id="mbt214332-cit-0010">
<string-name>
<surname>Hewitt</surname>, <given-names>S.H.</given-names>
</string-name>, <string-name>
<surname>Ali</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Mailhot</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Antonen</surname>, <given-names>C.R.</given-names>
</string-name>, <string-name>
<surname>Dodson</surname>, <given-names>C.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Butler</surname>, <given-names>S.J.</given-names>
</string-name> (<year>2019</year>) <article-title>A simple, robust, universal assay for real&#x02010;time enzyme monitoring by signalling changes in nucleoside phosphate anion concentration using a europium (III)&#x02010;based anion receptor</article-title>. <source>Chemical Science</source>, <volume>10</volume>, <fpage>5373</fpage>&#x02013;<lpage>5381</lpage>.<pub-id pub-id-type="pmid">31191895</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0011"><mixed-citation publication-type="journal" id="mbt214332-cit-0011">
<string-name>
<surname>Hughes</surname>, <given-names>R.R.</given-names>
</string-name>, <string-name>
<surname>Shaaban</surname>, <given-names>K.A.</given-names>
</string-name>, <string-name>
<surname>Ponomareva</surname>, <given-names>L.V.</given-names>
</string-name>, <string-name>
<surname>Horn</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Zhan</surname>, <given-names>C.G.</given-names>
</string-name> et al. (<year>2020</year>) <article-title>OleD loki as a catalyst for hydroxamate glycosylation</article-title>. <source>Chembiochem</source>, <volume>21</volume>, <fpage>952</fpage>&#x02013;<lpage>957</lpage>.<pub-id pub-id-type="pmid">31621997</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0012"><mixed-citation publication-type="journal" id="mbt214332-cit-0012">
<string-name>
<surname>Jiang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Xue</surname>, <given-names>Y.J.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>W.Y.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>X.R.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>S.Z.</given-names>
</string-name> et al. (<year>2015</year>) <article-title>The importance of start codon of <italic toggle="yes">nosM</italic> on nosiheptide production</article-title>. <source>Chinese Journal of Natural Medicines</source>, <volume>13</volume>, <fpage>854</fpage>&#x02013;<lpage>860</lpage>.<pub-id pub-id-type="pmid">26614460</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0013"><mixed-citation publication-type="journal" id="mbt214332-cit-0013">
<string-name>
<surname>Kanehisa</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Furumichi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tanabe</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sato</surname>, <given-names>Y.</given-names>
</string-name> &#x00026; <string-name>
<surname>Morishima</surname>, <given-names>K.</given-names>
</string-name> (<year>2017</year>) <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>. <source>Nucleic Acids Research</source>, <volume>45</volume>, <fpage>D353</fpage>&#x02013;<lpage>D361</lpage>.<pub-id pub-id-type="pmid">27899662</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0014"><mixed-citation publication-type="journal" id="mbt214332-cit-0014">
<string-name>
<surname>Khersonsky</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Lipsh</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Avizemer</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Ashani</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Goldsmith</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Leader</surname>, <given-names>H.</given-names>
</string-name> et al. (<year>2018</year>) <article-title>Automated design of efficient and functionally diverse enzyme repertoires</article-title>. <source>Molecular Cell</source>, <volume>72</volume>, <fpage>178</fpage>&#x02013;<lpage>186</lpage>.<pub-id pub-id-type="pmid">30270109</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0015"><mixed-citation publication-type="journal" id="mbt214332-cit-0015">
<string-name>
<surname>Kimber</surname>, <given-names>M.C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Moody</surname>, <given-names>C.J.</given-names>
</string-name> (<year>2008</year>) <article-title>Construction of macrocyclic thiodepsipeptides: synthesis of a nosiheptide 'southern hemisphere' model system</article-title>. <source>Chemical Communications</source>, <volume>5</volume>, <fpage>591</fpage>&#x02013;<lpage>593</lpage>.</mixed-citation></ref><ref id="mbt214332-bib-0016"><mixed-citation publication-type="journal" id="mbt214332-cit-0016">
<string-name>
<surname>Krauth</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Fedoryshyn</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Schleberger</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Luzhetskyy</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Bechthold</surname>, <given-names>A.</given-names>
</string-name> (<year>2009</year>) <article-title>Engineering a function into a glycosyltransferase</article-title>. <source>Chemistry &#x00026; Biology</source>, <volume>16</volume>, <fpage>28</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">19171303</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0017"><mixed-citation publication-type="journal" id="mbt214332-cit-0017">
<string-name>
<surname>Li</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>J.G.</given-names>
</string-name>, <string-name>
<surname>Mu</surname>, <given-names>S.C.</given-names>
</string-name>, <string-name>
<surname>Shang</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>Y.M.</given-names>
</string-name> et al. (<year>2020</year>) <article-title>Efficient O&#x02010;glycosylation of triterpenes enabled by protein engineering of plant glycosyltransferase UGT74AC1</article-title>. <source>ACS Catalysis</source>, <volume>10</volume>, <fpage>3629</fpage>&#x02013;<lpage>3639</lpage>.</mixed-citation></ref><ref id="mbt214332-bib-0018"><mixed-citation publication-type="journal" id="mbt214332-cit-0018">
<string-name>
<surname>Liang</surname>, <given-names>D.M.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>J.H.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>B.B.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>H.J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Qiao</surname>, <given-names>J.J.</given-names>
</string-name> (<year>2015</year>) <article-title>Glycosyltransferases: mechanisms and applications in natural product development</article-title>. <source>Chemical Society Reviews</source>, <volume>44</volume>, <fpage>8350</fpage>&#x02013;<lpage>8374</lpage>.<pub-id pub-id-type="pmid">26330279</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0019"><mixed-citation publication-type="journal" id="mbt214332-cit-0019">
<string-name>
<surname>Liu</surname>, <given-names>W.Y.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Xue</surname>, <given-names>Y.J.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>S.Z.</given-names>
</string-name> &#x00026; <string-name>
<surname>Chen</surname>, <given-names>Y.J.</given-names>
</string-name> (<year>2013</year>) <article-title>The C&#x02010;terminal extended serine residue is absolutely required in nosiheptide maturation</article-title>. <source>Chembiochem</source>, <volume>14</volume>, <fpage>573</fpage>&#x02013;<lpage>576</lpage>.<pub-id pub-id-type="pmid">23440918</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0020"><mixed-citation publication-type="journal" id="mbt214332-cit-0020">
<string-name>
<surname>Magiorakos</surname>, <given-names>A.P.</given-names>
</string-name>, <string-name>
<surname>Srinivasan</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Carey</surname>, <given-names>R.B.</given-names>
</string-name>, <string-name>
<surname>Carmeli</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Falagas</surname>, <given-names>M.E.</given-names>
</string-name>, <string-name>
<surname>Giske</surname>, <given-names>C.G.</given-names>
</string-name> et al. (<year>2012</year>) <article-title>Multidrug&#x02010;resistant, extensively drug&#x02010;resistant and pandrug&#x02010;resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance</article-title>. <source>Clinical Microbiology and Infection</source>, <volume>18</volume>, <fpage>268</fpage>&#x02013;<lpage>281</lpage>.<pub-id pub-id-type="pmid">21793988</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0021"><mixed-citation publication-type="journal" id="mbt214332-cit-0021">
<string-name>
<surname>Nidetzky</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Gutmann</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Zhong</surname>, <given-names>C.</given-names>
</string-name> (<year>2018</year>) <article-title>Leloir glycosyltransferases as biocatalysts for chemical production</article-title>. <source>ACS Catalysis</source>, <volume>8</volume>, <fpage>6283</fpage>&#x02013;<lpage>6300</lpage>.</mixed-citation></ref><ref id="mbt214332-bib-0022"><mixed-citation publication-type="journal" id="mbt214332-cit-0022">
<string-name>
<surname>Persson</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Palcic</surname>, <given-names>M.M.</given-names>
</string-name> (<year>2008</year>) <article-title>A high&#x02010;throughput pH indicator assay for screening glycosyltransferase saturation mutagenesis libraries</article-title>. <source>Analytical Biochemistry</source>, <volume>378</volume>, <fpage>1</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">18405657</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0023"><mixed-citation publication-type="journal" id="mbt214332-cit-0023">
<string-name>
<surname>Ryu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Eom</surname>, <given-names>M.S.</given-names>
</string-name>, <string-name>
<surname>Ko</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Han</surname>, <given-names>M.S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Lee</surname>, <given-names>H.S.</given-names>
</string-name> (<year>2014</year>) <article-title>A fluorescence&#x02010;based glycosyltransferase assay for high&#x02010;throughput screening</article-title>. <source>Bioorganic &#x00026; Medicinal Chemistry</source>, <volume>22</volume>, <fpage>2571</fpage>&#x02013;<lpage>2575</lpage>.<pub-id pub-id-type="pmid">24650699</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0024"><mixed-citation publication-type="journal" id="mbt214332-cit-0024">
<string-name>
<surname>Tan</surname>, <given-names>Y.Z.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Chen</surname>, <given-names>Y.J.</given-names>
</string-name> (<year>2022</year>) <article-title>Reprogramming the biosynthesis of precursor peptide to create a selenazole&#x02010;containing nosiheptide analogue</article-title>. <source>ACS Synthetic Biology</source>, <volume>11</volume>, <fpage>85</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">35006674</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0025"><mixed-citation publication-type="journal" id="mbt214332-cit-0025">
<string-name>
<surname>Tsutsumi</surname>, <given-names>L.S.</given-names>
</string-name>, <string-name>
<surname>Owusu</surname>, <given-names>Y.B.</given-names>
</string-name>, <string-name>
<surname>Hurdle</surname>, <given-names>J.G.</given-names>
</string-name> &#x00026; <string-name>
<surname>Sun</surname>, <given-names>D.Q.</given-names>
</string-name> (<year>2014</year>) <article-title>Progress in the discovery of treatments for <italic toggle="yes">C. difficile</italic> infection: a clinical and medicinal chemistry review</article-title>. <source>Current Topics in Medicinal Chemistry</source>, <volume>14</volume>, <fpage>152</fpage>&#x02013;<lpage>175</lpage>.<pub-id pub-id-type="pmid">24236721</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0026"><mixed-citation publication-type="journal" id="mbt214332-cit-0026">
<string-name>
<surname>Vinogradov</surname>, <given-names>A.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Suga</surname>, <given-names>H.</given-names>
</string-name> (<year>2020</year>) <article-title>Introduction to thiopeptides: biological activity, biosynthesis, and strategies for functional reprogramming</article-title>. <source>Cell Chemical Biology</source>, <volume>27</volume>, <fpage>1032</fpage>&#x02013;<lpage>1051</lpage>.<pub-id pub-id-type="pmid">32698017</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0027"><mixed-citation publication-type="journal" id="mbt214332-cit-0027">
<string-name>
<surname>Weis</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lim</surname>, <given-names>E.&#x02010;K.</given-names>
</string-name>, <string-name>
<surname>Bruce</surname>, <given-names>N.C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Bowles</surname>, <given-names>D.J.</given-names>
</string-name> (<year>2008</year>) <article-title>Engineering and kinetic characterisation of two glucosyltransferases from <italic toggle="yes">Arabidopsis thaliana</italic>
</article-title>. <source>Biochimie</source>, <volume>90</volume>, <fpage>830</fpage>&#x02013;<lpage>834</lpage>.<pub-id pub-id-type="pmid">18295607</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0028"><mixed-citation publication-type="journal" id="mbt214332-cit-0028">
<string-name>
<surname>Williams</surname>, <given-names>G.J.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Thorson</surname>, <given-names>J.S.</given-names>
</string-name> (<year>2007</year>) <article-title>Expanding the promiscuity of a natural&#x02010;product glycosyltransferase by directed evolution</article-title>. <source>Nature Chemical Biology</source>, <volume>3</volume>, <fpage>657</fpage>&#x02013;<lpage>662</lpage>.<pub-id pub-id-type="pmid">17828251</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0029"><mixed-citation publication-type="journal" id="mbt214332-cit-0029">
<string-name>
<surname>Wojtas</surname>, <given-names>K.P.</given-names>
</string-name>, <string-name>
<surname>Riedrich</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>J.Y.</given-names>
</string-name>, <string-name>
<surname>Winter</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Winkler</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Walter</surname>, <given-names>S.</given-names>
</string-name> et al. (<year>2016</year>) <article-title>Total synthesis of nosiheptide</article-title>. <source>Angewandte Chemie, International Edition</source>, <volume>55</volume>, <fpage>9772</fpage>&#x02013;<lpage>9776</lpage>.<pub-id pub-id-type="pmid">27345011</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0030"><mixed-citation publication-type="journal" id="mbt214332-cit-0030">
<string-name>
<surname>Xie</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Song</surname>, <given-names>X.Q.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>Y.X.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>M.Y.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>X.Z.</given-names>
</string-name> &#x00026; <string-name>
<surname>He</surname>, <given-names>L.M.</given-names>
</string-name> (<year>2019</year>) <article-title>Rapid determination of nosiheptide in feed based on dispersive SPE coupled with HPLC</article-title>. <source>Journal of Separation Science</source>, <volume>42</volume>, <fpage>706</fpage>&#x02013;<lpage>715</lpage>.<pub-id pub-id-type="pmid">30444321</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0031"><mixed-citation publication-type="journal" id="mbt214332-cit-0031">
<string-name>
<surname>Xu</surname>, <given-names>Y.C.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>S.Q.</given-names>
</string-name>, <string-name>
<surname>Bian</surname>, <given-names>L.Y.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>Z.L.</given-names>
</string-name>, <string-name>
<surname>Luo</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>Y.J.</given-names>
</string-name> et al. (<year>2022</year>) <article-title>Engineering of a UDP&#x02010;glycosyltransferase for the efficient whole&#x02010;cell biosynthesis of siamenoside I in <italic toggle="yes">Escherichia coli</italic>
</article-title>. <source>Journal of Agricultural and Food Chemistry</source>, <volume>70</volume>, <fpage>1601</fpage>&#x02013;<lpage>1609</lpage>.<pub-id pub-id-type="pmid">35099964</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0032"><mixed-citation publication-type="journal" id="mbt214332-cit-0032">
<string-name>
<surname>Zhang</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Guo</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>D.D.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Fan</surname>, <given-names>Y.F.</given-names>
</string-name>, <string-name>
<surname>Yin</surname>, <given-names>Y.</given-names>
</string-name> et al. (<year>2020</year>) <article-title>Mutational biosynthesis to generate novel analogs of nosiheptide featuring a fluorinated indolic acid moiety</article-title>. <source>Organic &#x00026; Biomolecular Chemistry</source>, <volume>18</volume>, <fpage>4051</fpage>&#x02013;<lpage>4055</lpage>.<pub-id pub-id-type="pmid">32412572</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0033"><mixed-citation publication-type="journal" id="mbt214332-cit-0033">
<string-name>
<surname>Zhang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yi</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Gao</surname>, <given-names>B.H.</given-names>
</string-name>, <string-name>
<surname>Su</surname>, <given-names>H.F.</given-names>
</string-name>, <string-name>
<surname>Bao</surname>, <given-names>Y.O.</given-names>
</string-name>, <string-name>
<surname>Shi</surname>, <given-names>X.M.</given-names>
</string-name> et al. (<year>2022</year>) <article-title>Functional characterization and protein engineering of a triterpene 3&#x02010;/6&#x02010;/2'&#x02010;O&#x02010;glycosyltransferase reveal a conserved residue critical for the regiospecificity</article-title>. <source>Angewandte Chemie, International Edition</source>, <volume>61</volume>, <elocation-id>e202113587</elocation-id>.<pub-id pub-id-type="pmid">34894044</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0034"><mixed-citation publication-type="journal" id="mbt214332-cit-0034">
<string-name>
<surname>Zhang</surname>, <given-names>N.N.</given-names>
</string-name>, <string-name>
<surname>Bittner</surname>, <given-names>J.P.</given-names>
</string-name>, <string-name>
<surname>Fiedler</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Beretta</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>de Mar&#x000ed;a</surname>, <given-names>P.D.</given-names>
</string-name>, <string-name>
<surname>Jakobtorweihen</surname>, <given-names>S.</given-names>
</string-name> et al. (<year>2022</year>) <article-title>Unraveling alcohol dehydrogenase catalysis in organic&#x02013;aqueous biphasic systems combining experiments and molecular dynamics simulations</article-title>. <source>ACS Catalysis</source>, <volume>12</volume>, <fpage>9171</fpage>&#x02013;<lpage>9180</lpage>.</mixed-citation></ref><ref id="mbt214332-bib-0035"><mixed-citation publication-type="journal" id="mbt214332-cit-0035">
<string-name>
<surname>Zhang</surname>, <given-names>Y.Y.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>S.H.</given-names>
</string-name>, <string-name>
<surname>Jin</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Dai</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>Y.J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Wu</surname>, <given-names>X.R.</given-names>
</string-name> (<year>2020</year>) <article-title>Efficient biocatalytic preparation of rebaudioside KA: highly selective glycosylation coupled with UDPG regeneration</article-title>. <source>Scientific Reports</source>, <volume>10</volume>, <fpage>6230</fpage>.<pub-id pub-id-type="pmid">32277148</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0036"><mixed-citation publication-type="journal" id="mbt214332-cit-0036">
<string-name>
<surname>Zhao</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>Z.L.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>X.N.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>Y.J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Wu</surname>, <given-names>X.R.</given-names>
</string-name> (<year>2020</year>) <article-title>Enzymatic monoglucosylation of rubusoside and the structure&#x02010;sweetness/taste relationship of monoglucosyl derivatives</article-title>. <source>Journal of Agricultural and Food Chemistry</source>, <volume>68</volume>, <fpage>8702</fpage>&#x02013;<lpage>8709</lpage>.<pub-id pub-id-type="pmid">32686405</pub-id></mixed-citation></ref><ref id="mbt214332-bib-0037"><mixed-citation publication-type="journal" id="mbt214332-cit-0037">
<string-name>
<surname>Zhou</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hamza</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Zhan</surname>, <given-names>C.G.</given-names>
</string-name> &#x00026; <string-name>
<surname>Thorson</surname>, <given-names>J.S.</given-names>
</string-name> (<year>2013</year>) <article-title>Assessing the regioselectivity of OleD&#x02010;catalyzed glycosylation with a diverse set of acceptors</article-title>. <source>Journal of Natural Products</source>, <volume>76</volume>, <fpage>279</fpage>&#x02013;<lpage>286</lpage>.<pub-id pub-id-type="pmid">23360118</pub-id></mixed-citation></ref></ref-list></back></article>